FI912470A0 - Behandling av haelsotillstaond och sjukdomar. - Google Patents

Behandling av haelsotillstaond och sjukdomar.

Info

Publication number
FI912470A0
FI912470A0 FI912470A FI912470A FI912470A0 FI 912470 A0 FI912470 A0 FI 912470A0 FI 912470 A FI912470 A FI 912470A FI 912470 A FI912470 A FI 912470A FI 912470 A0 FI912470 A0 FI 912470A0
Authority
FI
Finland
Prior art keywords
haelsotillstaond
sjukdomar
behandling
och
och sjukdomar
Prior art date
Application number
FI912470A
Other languages
English (en)
Finnish (fi)
Inventor
Rudolf Edgar Falk
Samuel S Asculai
Original Assignee
Norpharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4140639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI912470(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Norpharmco Inc filed Critical Norpharmco Inc
Publication of FI912470A0 publication Critical patent/FI912470A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI912470A 1989-09-21 1991-05-21 Behandling av haelsotillstaond och sjukdomar. FI912470A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA000612307A CA1340994C (en) 1989-09-21 1989-09-21 Treatment of conditions and disease
PCT/CA1990/000306 WO1991004058A2 (en) 1989-09-21 1990-09-18 Treatment of conditions and disease

Publications (1)

Publication Number Publication Date
FI912470A0 true FI912470A0 (fi) 1991-05-21

Family

ID=4140639

Family Applications (1)

Application Number Title Priority Date Filing Date
FI912470A FI912470A0 (fi) 1989-09-21 1991-05-21 Behandling av haelsotillstaond och sjukdomar.

Country Status (26)

Country Link
US (14) US6069135A (de)
EP (2) EP0445255B2 (de)
JP (1) JP3256761B2 (de)
KR (1) KR920700697A (de)
CN (1) CN1101228C (de)
AP (1) AP175A (de)
AT (2) ATE131068T1 (de)
AU (3) AU6433090A (de)
BR (1) BR9006924A (de)
CA (2) CA1340994C (de)
DE (2) DE69024039T3 (de)
DK (2) DK0445255T4 (de)
ES (2) ES2080837T5 (de)
FI (1) FI912470A0 (de)
HK (2) HK44797A (de)
HU (2) HU220758B1 (de)
IL (1) IL95745A (de)
IN (1) IN171745B (de)
LT (1) LT3545B (de)
NO (1) NO911952L (de)
RO (1) RO112812B1 (de)
RU (1) RU2146139C1 (de)
SG (1) SG49658A1 (de)
SK (1) SK459890A3 (de)
WO (1) WO1991004058A2 (de)
ZA (1) ZA907564B (de)

Families Citing this family (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
DE69132145T2 (de) * 1990-02-13 2000-09-21 Ethicon Inc Peritoneal wirksame medikamente
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
AU652784B2 (en) * 1990-10-18 1994-09-08 Shiseido Company Ltd. Combination of hyaluronic acid with medicinal ingredient and production thereof
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
CA2062659A1 (en) * 1991-03-12 1992-09-13 Yasutaka Igari Composition for sustained-release of erythropoietin
US6432405B1 (en) * 1991-03-15 2002-08-13 Duke University Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies
US5990095A (en) 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
CA2079205C (en) * 1992-09-25 1998-02-10 Rudolf Edgar Falk Use of hyaluronic acid and forms to prevent arterial restenosis
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
ATE173405T1 (de) * 1991-07-10 1998-12-15 Takeda Chemical Industries Ltd Arzneimittel auf basis von hyaluronsäure
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
CA2130762C (en) * 1994-08-24 1999-07-06 Eva Anne Turley Treatment of disease and conditions associated with macrophage infiltration
US5438075A (en) 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
CA2094203A1 (en) * 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
DE69435141D1 (de) * 1993-07-19 2008-10-30 Angiotech Pharm Inc Anti-angiogene Mittel und Verfahren zu deren Verwendung
EP0778776A1 (de) * 1994-08-30 1997-06-18 Hyal Pharmaceutical Corporation Hyaluronsaeure und derivate zur modulation der zellulaeren aktivitaet
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
EP1609477B1 (de) * 1994-12-12 2011-11-09 Omeros Corporation Bespüllungslösung und deren Verwendung zur perioperativen Hemmung von Schmerzen, Entzündungen und/oder Spasmen an einer Gefässstruktur
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
US6013641A (en) * 1995-09-28 2000-01-11 Sangstat Medical Corporation Use of hyaluronic acid as an immunosuppressant
JP2000507915A (ja) * 1995-10-23 2000-06-27 ハイアル・ファーマシューティカル・オーストラリア・リミテッド 遺伝子療法のためのｄｎａ担体としてのヒアルロン酸および異常な網膜血管新生を治療するためのｖｅｇｆアンチセンスｄｎａ
US5652273A (en) * 1995-11-30 1997-07-29 Henry; James Reduction of hair growth
JP2000513707A (ja) * 1995-12-01 2000-10-17 ハイアル ファーマスティカル コーポレイション 投与薬剤の目標化、治療薬および他のグリコサミノグリカン（ｇａｇｓ）
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
CA2166155C (en) * 1995-12-27 2008-02-05 Eva Anne Turley Agents binding to hyaluronic acid binding domains and the use thereof
JP2000502714A (ja) 1996-01-11 2000-03-07 ハイアル ファーマスティカル コーポレイション ヒアルロン酸の型の有効量の経口投与
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US20050101564A1 (en) * 1996-04-02 2005-05-12 Pilarski Linda M. Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US6787530B1 (en) * 1996-08-23 2004-09-07 Monash University Use of pregnane-diones as analgesic agents
WO1998013024A2 (en) * 1996-09-27 1998-04-02 Hyal Pharmaceutical Corporation Hyaluronic drug delivery system
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
CA2205692A1 (en) * 1997-05-16 1998-11-16 Hyal Pharmaceutical Corporation Method of administration for a therapeutic agent utilizing suitable forms of hyaluronic acid and combinations with electroporation
CA2205771C (en) * 1997-05-22 2002-05-14 Hyal Pharmaceutical Corporation Improved delivery of disease modifiers
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US5938658A (en) * 1997-12-02 1999-08-17 Tu; Hosheng Device and methods for treating canker sores by RF ablation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
PT1068870E (pt) 1998-04-03 2006-10-31 Ajinomoto Kk Agentes antitumorais
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
GB9810127D0 (en) * 1998-05-13 1998-07-08 Ml Lab Plc Prevention of surgical adhesions
US6391861B1 (en) 1998-05-14 2002-05-21 The Trustees Of Columbia University In The City Of New York Method for the prevention of tissue elastic fiber injury
US6663874B2 (en) 1998-11-02 2003-12-16 Victor Stevens Composition to alleviate pain and topical method of applying same
WO2000038647A1 (de) * 1998-12-23 2000-07-06 Esparma Gmbh Mittel zum schutz der haut, enthaltend ein aus hyaluronsäure durch hydrolyse hergestelltes fragmentgemisch
AU773984B2 (en) * 1999-01-13 2004-06-10 Alchemia Oncology Pty Limited A composition and method for the enhancement of the efficacy of drugs
NZ512676A (en) * 1999-01-13 2003-01-31 Meditech Res Ltd A composition and method for the enhancement of the efficacy of drugs
AU3356600A (en) * 1999-02-04 2000-08-25 Genzyme Corporation Prevention of abscess formation
DK1091750T3 (da) * 1999-02-26 2009-12-21 Maas Biolab Llc Cerebrospinalt og vaskulært farmaceutisk præparat og fremgangsmåde til fremstilling heraf
EP1206283A2 (de) * 1999-05-17 2002-05-22 Aesgen, Inc. Verbesserte zelluläre aufnahme von bioaktiven wirkstoffen
JP4450456B2 (ja) * 1999-09-27 2010-04-14 株式会社マルハニチロ水産 皮脂産生抑制剤
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
CZ20022372A3 (cs) * 1999-12-13 2002-11-13 Bioniche Life Sciences Inc. Terapeuticky pouľitelné syntetické oligonukleotidy
NZ520312A (en) * 1999-12-28 2003-08-29 Bioniche Life Sciences Inc Hyaluronic acid in the treatment of cancer
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
DK1142566T3 (da) 2000-04-07 2004-02-09 Medidom Lab Oftalmologiske formuleringer på basis af ciclosporin, hyaluronsyre og polysorbat
EP2267026A1 (de) * 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albuminfusionsproteine
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
EP1292314A2 (de) * 2000-05-23 2003-03-19 The Trustees of Columbia University in the City of New York Methode zur behandlung von krankheiten der atemwege durch einsatz von glycosaminoglycane
US6221166B1 (en) 2000-06-07 2001-04-24 Simplus Systems Corporation Multi-thermal zone shielding apparatus
US7255883B2 (en) * 2000-06-23 2007-08-14 Healagenics, Inc. Agent for reduction of scar formation by using wound alkalinization
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US7285284B2 (en) * 2000-09-08 2007-10-23 Kuhnau Stephen C Cosmetic composition, method of use and method of making
EP1328278A4 (de) * 2000-09-26 2004-06-16 Univ Temple Analgetische und glucosamin-zusammensetzungen
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
BR0114713A (pt) * 2000-10-16 2004-01-13 Neopharm Inc Formulação lipossÈmica de mitoxantrona
CA2428753C (en) * 2000-11-17 2013-05-21 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
CN1131036C (zh) * 2001-02-28 2003-12-17 中国人民解放军第三军医大学 N－乙酰－d－氨基葡萄糖在制备抑制放化疗副反应药物中的应用
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
US20060198815A1 (en) * 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
JP2005511477A (ja) * 2001-03-19 2005-04-28 プラエシス ファーマシューティカルズ インコーポレーテッド 持続放出のための医薬調合物
JP5024497B2 (ja) * 2001-03-27 2012-09-12 キユーピー株式会社 経口用肌改善剤、肌改善方法及び肌改善用食品組成物
US8403954B2 (en) 2001-05-22 2013-03-26 Sanostec Corp. Nasal congestion, obstruction relief, and drug delivery
CA2446739A1 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US7544374B2 (en) 2001-08-14 2009-06-09 Tel Aviv University Future Technology Development L.P. Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
AU2002325635C1 (en) * 2001-08-27 2008-09-25 Alchemia Oncology Pty Limited Improved therapeutic protocols
CN1578677A (zh) * 2001-08-27 2005-02-09 美迪泰克研究有限公司 改良的治疗方案
US7354910B2 (en) * 2001-10-18 2008-04-08 Seikagaku Kogyo Kabushiki Kaisha Agent for treating inflammatory bowel diseases
WO2003041723A1 (de) * 2001-11-12 2003-05-22 Reinmueller Johannes Pharmazeutische anwendungen von hyaluronsäure-präparaten
US6806259B2 (en) * 2001-12-21 2004-10-19 Soft Gel Technologies, Inc. Hyaluronic Acid in soft gel form
PT1463751E (pt) * 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
RU2213557C2 (ru) * 2001-12-26 2003-10-10 Закрытое акционерное общество "Аксис" Фармацевтическая композиция, обладающая тромболитическими, противовоспалительными и цитопротективными свойствами
US6887270B2 (en) 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US7993390B2 (en) * 2002-02-08 2011-08-09 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US8506647B2 (en) * 2002-02-14 2013-08-13 Boston Scientific Scimed, Inc. System for maintaining body canal patency
WO2003070256A1 (en) * 2002-02-15 2003-08-28 Research Development Foundation Hyaluronic acid mediated adenoviral transduction
FR2836336B1 (fr) * 2002-02-26 2004-08-27 Diana Ingredients Utilisation dans un traitement cosmetique d'une fraction phenolique riche en dihydrochalcones
AU2003217982A1 (en) * 2002-03-06 2003-09-22 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
JP2005530768A (ja) * 2002-05-09 2005-10-13 メディジーンズ 血漿または血清を含有した創傷治療用医薬組成物
ITMI20020986A1 (it) * 2002-05-10 2003-11-10 Acraf Composizione a base di diclofenac per il trattamento topico di affezioni del cavo orofaringeo
EP1539193A4 (de) * 2002-07-03 2010-05-05 Pericor Science Inc Zusammensetzungen von hyaluronsäure und verwendungsverfahren
CN1802152A (zh) * 2002-08-01 2006-07-12 艾斯根公司 用谷氨酰胺改善癌症的治疗
US6979458B1 (en) 2002-09-11 2005-12-27 Kenneth A. Martin Beverage and additive for wellness
US20040253227A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery
US6900173B2 (en) * 2002-09-11 2005-05-31 Kenneth A. Martin Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery
US20040253296A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Food bar for treating musculoskeletal disorders
US6660308B1 (en) 2002-09-11 2003-12-09 Kenneth A. Martin Beverage and additive for the ill
US20040254095A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Supplement for treating musculoskeletal disorders
DE10246340A1 (de) * 2002-10-04 2004-04-29 Wohlrab, David, Dr. Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung
EP1603548A4 (de) * 2003-02-05 2007-10-10 Myriad Genetics Inc Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen
US6946551B2 (en) 2003-03-12 2005-09-20 New Life Resources, Llc Preparation of hyaluronic acid from eggshell membrane
US20080063677A1 (en) * 2004-03-10 2008-03-13 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20040180025A1 (en) * 2003-03-12 2004-09-16 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20050136126A1 (en) * 2003-03-17 2005-06-23 Cambridgemed, Inc. Agent for reduction of scar formation by using wound alkalinization
JP4212970B2 (ja) * 2003-06-30 2009-01-21 株式会社キーエンス 安全リレーシステム
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US6913968B2 (en) * 2003-07-30 2005-07-05 International Business Machines Corporation Method and structure for vertical DRAM devices with self-aligned upper trench shaping
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
BRPI0414843A (pt) * 2003-09-30 2006-11-21 John Arthur Disegi revestimentos de ácido hialurÈnico antimicrobiais para implantes ortopédicos
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
EP1686963A1 (de) * 2003-10-27 2006-08-09 PSivida Inc. Suspensionsabgabesysteme für die verzögerte und kontrollierte lokale freisetzung von pharmazeutika
US20050100537A1 (en) * 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
US7976858B2 (en) 2004-01-13 2011-07-12 The Hospital For Special Surgery Drug delivery to a joint
DE102004002001A1 (de) * 2004-01-14 2005-08-11 Reinmüller, Johannes, Dr.med. Mittel zur Behandlung von entzündlichen Erkrankungen
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
US8580315B2 (en) * 2004-03-10 2013-11-12 Esm Technologies, Llc Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations
US7699783B2 (en) * 2004-04-08 2010-04-20 Techniscan, Inc. Method for imaging and treating a breast
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AR051429A1 (es) * 2004-04-20 2007-01-17 Stenti De Pirillo Haydee A Composicion farmaceutica ozonizada y metodos para obtenerla
CN1946906A (zh) * 2004-04-29 2007-04-11 吉斯通护岸系统股份有限公司 用于墙、护墙和类似物的饰面
BRPI0512394A (pt) * 2004-06-22 2008-03-11 Pro Pharmaceuticals Inc composições e métodos para co-distribuição de fármacos anticáncer, fármacos antiangiogênicos e um polissacarìdeo
DE102004030155B4 (de) * 2004-06-22 2020-04-23 Robert Bosch Gmbh Dosiervorrichtung und Verfahren zum Betrieb derselben
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20060040894A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid
US7414021B2 (en) * 2004-10-01 2008-08-19 Vincent Carmine Giampapa Method and composition for restoration of age related tissue loss in the face or selected areas of the body
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
CN101115475A (zh) 2004-12-10 2008-01-30 塔利马治疗公司 用于治疗指甲单位病症的组合物和方法
US20060292250A1 (en) * 2005-06-23 2006-12-28 Suracell, Inc. Supplement composition and method of use for enhancement of anti-inflammation process
US7276257B2 (en) * 2005-07-22 2007-10-02 The Hong Kong University Of Science And Technology Schisandrin B preparation
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
CN103784960A (zh) 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
US20070048391A1 (en) * 2005-08-23 2007-03-01 Cambridgemed, Inc. Composition for reduction of scar formation on wound scar
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
US20070059276A1 (en) * 2005-09-07 2007-03-15 Amo Regional Holdings Bi-modal hyaluronate
US8623354B2 (en) * 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US8598144B1 (en) 2005-11-10 2013-12-03 Reyn Pharma, Llc Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US9492381B1 (en) 2005-11-10 2016-11-15 Reyn Pharma, Llc Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
EP2046119A2 (de) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Behandlung von psychiatrischen störungen
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
CN101522164B (zh) 2006-09-13 2014-03-26 提升肤质产品公司 用于治疗皮肤的化妆品组合物及其方法
JP5864834B2 (ja) * 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス プロテアーゼ耐性のインスリンアナログ
WO2008070118A1 (en) * 2006-12-05 2008-06-12 Landec Corporation Drug delivery
KR101339096B1 (ko) * 2006-12-26 2013-12-09 보미 파텔 프람로즈 과색소침착 피부용 피부 미백 조성물
AU2008210557B2 (en) 2007-01-30 2013-08-01 Cypress Pharmaceutical, Inc. Hyaluronate compositions
AU2008222592B2 (en) * 2007-03-02 2013-09-26 Detsamma Investments Pty Ltd Compositions and methods for delivery of anti-cancer agents
US20080268039A1 (en) * 2007-03-06 2008-10-30 Soft Gel Technologies, Inc. Loquat compositions
US8366617B2 (en) * 2007-05-15 2013-02-05 CVUS Clinical Trials, LLC Breast scanning system
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
MX349677B (es) 2007-11-13 2017-08-08 Meritage Pharma Inc Composiciones corticosteroides.
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090131386A1 (en) * 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
PT2254906T (pt) 2008-03-18 2017-01-03 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US8163716B1 (en) 2008-06-30 2012-04-24 Smith James D Method of administering hyaluronan formulation for the amelioration of osteophytes
US8178511B1 (en) 2008-07-02 2012-05-15 Smith James D Method of administering hyaluronan formulation for the amelioration of osteopenia
IT1397247B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi agenti regolatori dell'attivita' citochinica
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US8273725B2 (en) 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9669053B2 (en) 2010-07-26 2017-06-06 Chemotherapeutics, Llc Compositions and methods for enhancing the effectiveness of systemic, HIPEC, IP, and related cancer treatments
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
EP3536307B1 (de) 2011-06-03 2021-10-20 ALLERGAN Industrie, SAS Dermale füllstoffzusammensetzungen mit antioxidantien
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
TW201249843A (en) * 2011-06-14 2012-12-16 Univ Kaohsiung Medical Processes for preparing amine salts of KMUP-3 and use thereof
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
ES2667854T3 (es) * 2011-07-07 2018-05-14 Holy Stone Healthcare Co., Ltd. Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación
US20150359798A1 (en) * 2011-09-06 2015-12-17 Jansfat Biotechnology Co., Ltd. Piperazinyl derivative reduces high-fat diet-induced accumulation of fat in the livers, therapeutically
EP2567697A1 (de) 2011-09-12 2013-03-13 Almirall, S.A. Topische pharmazeutische Zusammensetzungen
TWI466675B (zh) * 2011-09-16 2015-01-01 Univ China Medical 用於抑制發炎之醫藥組合物
GB201118198D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
GB201118193D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to oranic compounds
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
RU2497201C1 (ru) * 2012-03-28 2013-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ увеличения выживаемости кожного лоскута в условиях редуцированного кровообращения миноксидилом
RU2497200C1 (ru) * 2012-03-28 2013-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ фармакологической коррекции ишемии скелетной мышцы миноксидилом
US9925143B2 (en) 2012-04-18 2018-03-27 Ramot At Tel-Aviv University Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
ITPD20120173A1 (it) 2012-05-31 2013-12-01 Fidia Farmaceutici "nuovo sistema di rilascio di proteine idrofobiche"
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ITMI20121316A1 (it) 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
FR3000670B1 (fr) * 2013-01-10 2015-02-27 Oreal Composition cosmetique apaisante a base d'acide salicylique.
RU2015143995A (ru) 2013-03-14 2017-04-20 Халлюкс, Инк. Способ лечения инфекций, заболеваний или расстройств ногтевого ложа
CN105120889B (zh) 2013-04-03 2018-04-13 雪松-西奈医学中心 通过调节乙酰透明质酸和透明质酸酶活性而治疗炎性病状
GR1008308B (el) 2013-05-31 2014-10-02 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Τοπικες φαρμακευτικες και ιατροτεχνολογικες συνθεσεις που περιεχουν συνδυασμους σουκραλφατης, υαλουρονικου οξεος, αργινινης και ενος φυσικου ενυδατικου παραγοντα
KR101439032B1 (ko) * 2013-06-13 2014-09-05 동아에스티 주식회사 피록시캄과 히알루론산을 포함하는 골관절염 치료를 위한 액상 조성물
CN103330945B (zh) * 2013-07-16 2014-07-02 山东大学齐鲁医院 平阳霉素联合透明质酸钠在治疗淋巴管畸形药物中的应用
CN103341157A (zh) * 2013-07-25 2013-10-09 山东大学齐鲁医院 平阳霉素联合透明质酸钠在治疗静脉畸形药物中的应用
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10583084B2 (en) 2014-06-26 2020-03-10 Ramot At Tel-Aviv University Ltd. Liposomal formulations for delivery of nucleic acids
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3435977A4 (de) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. Pharmazeutische steroidhormonzusammensetzung
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN110087674B (zh) 2016-12-16 2023-01-03 诺和诺德股份有限公司 含胰岛素的药物组合物
WO2019173261A1 (en) * 2018-03-06 2019-09-12 Samuel Asculai Composition and method to treat cancer using hyaluronic acid
CN109512825A (zh) * 2018-12-29 2019-03-26 江苏靶标生物医药研究所有限公司 一种铂类化合物和透明质酸钠的组合物及其应用
CN110467689A (zh) * 2019-09-09 2019-11-19 山东众山生物科技有限公司 一种透明质酸衍生物及其制备方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583096A (en) * 1949-01-15 1952-01-22 Searle & Co Process for the production of high viscosity hyaluronic acid
GB769287A (en) * 1954-08-18 1957-03-06 American Home Prod Preparation of partially depolymerized hyaluronic acid and therapeutic compositions thereof
FR3715M (fr) * 1964-06-11 1965-11-29 Lucien Nouvel Antithermiques et antirhumatismaux améliorés.
US3887703A (en) * 1967-03-24 1975-06-03 Oreal Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions
GB1283892A (en) * 1970-06-08 1972-08-02 Irwin Irville Lubowe Improvements in and relating to medicinal compositions for application to the skin and/or hair
DE2364373A1 (de) * 1973-12-22 1975-07-10 Hahn Carl Dr Gmbh Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4282216A (en) * 1977-04-20 1981-08-04 Johnson & Johnson Topical anti-inflammatory drug therapy
US4296104A (en) * 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
JPS57183707A (en) * 1981-05-02 1982-11-12 Shiseido Co Ltd Cosmetic
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4582685A (en) 1982-10-07 1986-04-15 Helena Laboratories Corporation Test kit for performing a medical test
US4711884A (en) * 1983-02-28 1987-12-08 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
AU570998B2 (en) * 1983-09-07 1988-03-31 Takeda Chemical Industries Ltd. Topical steroid compositions for acne
IN163192B (de) * 1983-10-11 1988-08-20 Fidia Spa
IL74715A0 (en) * 1984-03-27 1985-06-30 Univ New Jersey Med Biodegradable matrix and methods for producing same
CH663353A5 (de) * 1984-03-28 1987-12-15 Joaquin Amat Larraz Mittel gegen krebs.
US4716224A (en) * 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
US4735902A (en) * 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
DE3686275T2 (de) * 1985-01-11 1993-03-18 Teijin Ltd Praeparate mit verzoegerter freisetzung.
SE8501723L (sv) * 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
JPS61233622A (ja) * 1985-04-09 1986-10-17 Riken Vitamin Co Ltd 眼薬組成物
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
EP0207638B1 (de) * 1985-06-04 1990-12-19 Teijin Limited Arzneizubereitung mit verzögerter Wirkstoffabgabe
US4617319A (en) * 1985-06-13 1986-10-14 American Cyanamid Company Method of treating multiple sclerosis
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
FR2584606A1 (fr) * 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
IN166447B (de) * 1985-11-27 1990-05-12 Ethicon Inc
EP0224987B1 (de) * 1985-11-29 1992-04-15 Biomatrix, Inc. Arzneistoffabgabesysteme auf Basis von Hyaluronan, dessen Derivaten und Salzen sowie Verfahren zu deren Herstellung
JP2604135B2 (ja) * 1986-02-28 1997-04-30 ライオン株式会社 口腔骨疾患治療剤
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
JPS62212335A (ja) * 1986-03-14 1987-09-18 Mitsui Toatsu Chem Inc ２−アリ−ル−２−メチルプロピルエ−テル誘導体およびそれを有効成分として含有する殺虫剤
JPS62240628A (ja) * 1986-03-26 1987-10-21 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
JPS6345223A (ja) * 1986-04-04 1988-02-26 Ueno Seiyaku Oyo Kenkyusho:Kk ひと免疫不全ウイルス性疾患処置剤
EP0240098A3 (de) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren
EP0244178A3 (de) * 1986-04-28 1989-02-08 Iolab, Inc Intraokuläre Mittel und Verfahren zu deren Verwendung
US4808576A (en) * 1986-04-28 1989-02-28 Mobay Corporation Remote administration of hyaluronic acid to mammals
JPH06104624B2 (ja) * 1986-05-07 1994-12-21 太郎 小木曽 経皮吸収剤
IT1189111B (it) * 1986-05-08 1988-01-28 Minnesota Mining & Mfg Elementi radiografici con un ridotto cross-over e ridotta colorazione residua
JPS62287041A (ja) * 1986-06-05 1987-12-12 Kawasaki Steel Corp 高合金鋼焼結材料の製造方法
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
JPS6311678A (ja) 1986-06-30 1988-01-19 Hitachi Chem Co Ltd 無電解銅めつき法
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
JPH07110349B2 (ja) * 1986-11-04 1995-11-29 セイレイ工業株式会社 籾摺選別装置
NZ222695A (en) * 1986-11-29 1990-03-27 Ueno Seiyaku Oyo Kenkyujo Kk Synergistic antiviral compositions
EP0270319A3 (de) * 1986-12-03 1990-03-28 Logistics Data Systems, Inc. Video-C.A.D.-System
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
GB8706052D0 (en) * 1987-03-13 1987-04-15 Medical Research Int Therapeutic compositions
AU604542B2 (en) * 1987-03-19 1990-12-20 Arthropharm Pty Ltd Polysulphated polysaccharide complexes
EP0285357A3 (de) * 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Bekämpfung von Retroviren
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
US5079236A (en) * 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
GB8713747D0 (en) * 1987-06-12 1987-07-15 Unilever Plc Skin treatment composition
GB8715242D0 (en) * 1987-06-29 1987-08-05 Wood E M Fenclofenac as immunosuppressant drug
KR0131330B1 (ko) * 1987-07-01 1998-04-17 맥스 디. 헨슬레이 피브린 침착 또는 유착을 방지하기 위한 방법 및 치료 조성물
US4900550A (en) * 1987-08-19 1990-02-13 Amy Allene Cosmetiques, Inc. Skin care cosmetic regime
EP0391909B1 (de) * 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Cyclosporin-augenmittel
ES2054815T3 (es) * 1987-09-08 1994-08-16 Takeda Chemical Industries Ltd Citoquinas insolubilizadas en agua.
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
JPH01151462A (ja) * 1987-12-09 1989-06-14 Terumo Corp 腹膜灌流液
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
DK505588D0 (da) * 1988-02-26 1988-09-09 Jesper Hamburger Middel og anvendelse af samme
US4943560A (en) * 1988-04-06 1990-07-24 Regents Of The University Of Minnesota Solvent system for chronic vascular infusion of hydrophobic drugs
JPH01265970A (ja) * 1988-04-19 1989-10-24 Shiseido Co Ltd ヒアルロン酸を含有させたコラーゲン水溶液又は水分散液
US4840341A (en) 1988-05-09 1989-06-20 Hasegawa Gary K Clip and holder
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
JPH01287041A (ja) * 1988-05-13 1989-11-17 Rooman Kogyo:Kk 徐放性製剤
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
DE3900198A1 (de) * 1989-01-05 1990-07-12 Merck Patent Gmbh Topisch anwendbare pharmazeutische zubereitung
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
US5156846A (en) * 1989-02-23 1992-10-20 University Of Utah Percutaneous drug delivery system
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5053222A (en) * 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
US5181276A (en) * 1990-02-22 1993-01-26 Baxter International Inc. Infection resistant products
US5290271A (en) * 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
US5091182A (en) * 1990-07-23 1992-02-25 Syntex (U.S.A.) Inc. Dispensing units for ketorolac topical gel formlations
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
DE69320078T2 (de) * 1992-02-04 1999-03-25 Baxter Int Peritonealdialyselösungen die mindestens ein Dipeptid enthalten

Also Published As

Publication number Publication date
HK44797A (en) 1997-04-18
US5914314A (en) 1999-06-22
US5827834A (en) 1998-10-27
US5811410A (en) 1998-09-22
DE69024039T3 (de) 2002-12-12
LT3545B (en) 1995-11-27
US5852002A (en) 1998-12-22
IN171745B (de) 1992-12-26
DK0656213T3 (da) 2003-03-17
EP0656213A1 (de) 1995-06-07
AU6433090A (en) 1991-04-18
ATE131068T1 (de) 1995-12-15
US6048844A (en) 2000-04-11
ATE227587T1 (de) 2002-11-15
US5985851A (en) 1999-11-16
US20040019011A1 (en) 2004-01-29
ES2186693T3 (es) 2003-05-16
ES2080837T5 (es) 2002-03-01
BR9006924A (pt) 1991-12-10
KR920700697A (ko) 1992-08-10
DK0445255T3 (da) 1996-03-04
LTIP1582A (en) 1995-06-26
DE69034018D1 (de) 2002-12-19
NO911952D0 (no) 1991-05-21
EP0445255A1 (de) 1991-09-11
AU5227493A (en) 1994-03-03
JPH04504579A (ja) 1992-08-13
HU211953A9 (en) 1996-01-29
CA2042034A1 (en) 1991-03-22
HUT64699A (en) 1994-02-28
AU674894C (en) 2002-03-14
SG49658A1 (en) 1998-06-15
RU2146139C1 (ru) 2000-03-10
DK0445255T4 (da) 2002-02-18
CN1101228C (zh) 2003-02-12
DE69024039D1 (de) 1996-01-18
HK1005985A1 (en) 1999-02-05
US6194392B1 (en) 2001-02-27
EP0656213B1 (de) 2002-11-13
NO911952L (no) 1991-07-05
RO112812B1 (ro) 1998-01-30
CN1051503A (zh) 1991-05-22
EP0445255B2 (de) 2001-12-05
US5985850A (en) 1999-11-16
US5932560A (en) 1999-08-03
US20060128655A1 (en) 2006-06-15
ES2080837T3 (es) 1996-02-16
IL95745A0 (de) 1991-06-30
AU674894B2 (en) 1997-01-16
WO1991004058A2 (en) 1991-04-04
EP0445255B1 (de) 1995-12-06
US5830882A (en) 1998-11-03
AP175A (en) 1992-04-03
JP3256761B2 (ja) 2002-02-12
AP9000206A0 (en) 1990-10-31
DE69034018T2 (de) 2003-07-24
IL95745A (en) 1999-09-22
WO1991004058A3 (en) 1991-09-19
US6069135A (en) 2000-05-30
HU907339D0 (en) 1991-08-28
CA1340994C (en) 2000-05-16
DE69024039T2 (de) 1996-06-13
SK459890A3 (en) 2000-09-12
US5929048A (en) 1999-07-27
ZA907564B (en) 1991-08-28
HU220758B1 (hu) 2002-05-28
AU1485097A (en) 1997-05-22

Similar Documents

Publication Publication Date Title
FI912470A0 (fi) Behandling av haelsotillstaond och sjukdomar.
FI892019A0 (fi) Foerfarande och anordning foer kontinuerlig kokning av sellulosa.
FI891655A (fi) Foerfarande och anordning foer reglering av en bergborrningsmaskin.
FI902724A0 (fi) Vaetskebehandling och vaetske-extraktion av pappersmassa.
FI890395A0 (fi) Foerfarande och anlaeggning foer framstaellning av nickelfinsten.
FI905473A0 (fi) Rengoeringssammansaettningar av vaetehaltiga fluorklorkolvaeten och partiellt fluorerade alkanoler.
FI890287A (fi) Foerfarande och tejp foer sammanfogning av pappersbanor.
FI905847A (fi) Kombination av tryckvaetskemekanism och en daertill kopplad skivbroms.
FI890756A0 (fi) Foerfarande foer sortering av massasuspension och sorteringsapparat.
FI892356A0 (fi) Foerfarande och anordning foer behandling av fibersuspension.
FI890504A0 (fi) Foerfarande och anordning foer kontroll av trafikfoerhaollanden.
FI890581A (fi) Foerfarande och anordning foer traening av rygg.
FI893934A (fi) Foerfarande och kylarrangemang foer avkylning av en byggnad.
FI891343A0 (fi) Foerfarande och anordning foer upphettning av en pappers- eller kartongbana.
FI890250A0 (fi) Foerfarande och anordning foer provtagning av en roerlig materialbana.
FI891016A (fi) Anordning foer gruppkvistning och kapning av traedstammar.
FI891779A0 (fi) Foerfarande och anordning foer behandling av kroppens ryggsida.
FI890808A0 (fi) Foerfarande och anordning foer flyttning av klumpplantor.
FI891047A (fi) Anlaeggning foer framstaellning och anvaendning av betongmassa.
FI890639A (fi) Foerfarande och anlaeggning foer genomfoerande av en energiproduktionsprocess.
FI891317A0 (fi) Foerfarande och anordning foer torkning av bulkvara.
FI890434A0 (fi) Skyddsyta foer foerhindrande av korrosion och slitage av industrimaskiner och -anordningar.
FI891421A (fi) Foerfarande och anordning foer kompostering av kvaevehaltigt organiskt avfall.
FI891617A (fi) Foerfarande och anordning foer insamling av fraestorv.
FI890400A0 (fi) Foerbaettrat stroematerial foer djur och foerfarande foer framstaellning av stroematerialet.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: HYAL PHARMACEUTICAL CORPORATION